Literature DB >> 12482739

Calcimimetics: therapeutic potential in hyperparathyroidism.

Adi Cohen1, Shonni J Silverberg.   

Abstract

Calcium homeostasis is essential for the normal function of many organ systems. The recently cloned extracellular calcium-sensing receptor plays a central role in this process and thus represents an important target for therapeutic agents aimed at treating disorders of calcium metabolism. Compounds, such as the phenylalkylamines NPS 568 and AMG 073, act as agonists of calcium at this receptor. These calcimimetic agents hold promise as potential treatments for diseases of parathyroid hyperfunction, such as primary and secondary hyperparathyroidism.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12482739     DOI： 10.1016/s1471-4892(02)00210-2

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  4 in total

1.  Identification of a novel extracellular cation-sensing G-protein-coupled receptor.

Authors:  Min Pi; Pieter Faber; George Ekema; P David Jackson; Anthony Ting; Nancy Wang; Michelle Fontilla-Poole; Robert W Mays; Kurt R Brunden; John J Harrington; L Darryl Quarles
Journal:  J Biol Chem       Date:  2005-09-30       Impact factor: 5.157

Review 2.  Persistent and recurrent hyperparathyroidism.

Authors:  Nadine R Caron; Cord Sturgeon; Orlo H Clark
Journal:  Curr Treat Options Oncol       Date:  2004-08

3.  GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome.

Authors:  Min Pi; Ling Chen; Min-Zhao Huang; Wenyu Zhu; Brian Ringhofer; Junming Luo; Lane Christenson; Benyi Li; Jianghong Zhang; P David Jackson; Pieter Faber; Kurt R Brunden; John J Harrington; L Darryl Quarles
Journal:  PLoS One       Date:  2008-12-03       Impact factor: 3.240

Review 4.  Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators.

Authors:  Jianxin Hu; Allen M Spiegel
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.